Get the Stockscreener App
0.8694
1.34%
0.0115
Pre-market:
.86
-0.0094
-1.08%
Aptorum Group Ltd stock is traded at $0.8694, with a volume of 76,903.
It is up +1.34% in the last 24 hours and up +5.59% over the past month.
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.
See More
Previous Close:
$0.8579
Open:
$0.85
24h Volume:
76,903
Relative Volume:
0.53
Market Cap:
$7.08M
Revenue:
$431.40K
Net Income/Loss:
$-1.95M
P/E Ratio:
-7.0226
EPS:
-0.1238
Net Cash Flow:
$-726.80K
1W Performance:
-25.69%
1M Performance:
+5.59%
6M Performance:
-30.45%
1Y Performance:
-24.40%
1-Day Range:
$0.831
$0.9076
1-Week Range:
$0.81
$1.21
52-Week Range:
$0.65
$4.47
Aptorum Group Ltd Stock (APM) Company Profile
Compare APM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APM
Aptorum Group Ltd
|
0.8694 | 7.08M | 431.40K | -1.95M | -726.80K | -0.1238 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aptorum Group Ltd Stock (APM) Latest News
APM News | APTORUM GROUP LTD-CLASS A (NASDAQ:APM) - ChartMill
Aptorum Shareholders Approve Proposed Merger With DiamiR Biosciences - Moomoo
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Aptorum Group Limited Announces Board of Directors Appointments - marketscreener.com
Aptorum shareholders approve merger with DiamiR Biosciences By Investing.com - Investing.com South Africa
Aptorum Group Limited and DiamiR Biosciences Corp. Shareholders Approve Merger Transaction - Quiver Quantitative
Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences - Yahoo Finance
Aptorum Group Limited (APM) Hovers Near Support at $0.80 After Marginal DeclinePut Spread Alert - newsline.com
APM | Aptorum Group Limited Class Insider Trading - Quiver Quantitative
APM Technical Analysis | Trend, Signals & Chart Patterns | APTORUM GROUP LTD-CLASS A (NASDAQ:APM) - ChartMill
Why Is Aptorum Group Limited (APM.PA) Stock Down Today? - Meyka
TradingKey - TradingKey
Aptorum Group to Domesticate, Merge with DiamiR (NASDAQ: APM) - Stock Titan
Is Aptorum (APM) stock considered high volatility (Slight Gain) 2026-04-22Swing Trade - newser.com
Can Aptorum (APM) Stock Double in 2026 | Price at $0.93, Up 0.29%Continuation Pattern - Newser
XBIO PE Ratio & Valuation, Is XBIO Overvalued - Intellectia AI
APRE PE Ratio & Valuation, Is APRE Overvalued - Intellectia AI
APM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Aptorum Group Soars Over 20% as Market Deciphers Regulatory Chaos and Sector Growth Signals - Bitget
DiamiR merger gives Aptorum (NASDAQ: APM) holders 30% of new Niki BioSolutions - stocktitan.net
Aptorum (NASDAQ: APM) to merge with DiamiR; domestication and share issuance - Stock Titan
Direxion Daily AMZN Bull 2X Shares (NASDAQ:AMZU) Short Interest Up 22.7% in March - Defense World
APTORUM GROUP PB Ratio: 0.29 | Possible Value Trap - GuruFocus
Going concern warning and high risk profile at Aptorum Group (NASDAQ: APM) - Stock Titan
Aptorum (NASDAQ: APM) delays DiamiR merger cutoff to June 30, 2026 - Stock Titan
If You Invested $1,000 in Aptorum Group Ltd (APM) - Stock Titan
Aptorum Group (APM) Stock Analysis Report | Financials & Insights - Benzinga Japan
[6-K] Aptorum Group Ltd Current Report (Foreign Issuer) | APM SEC FilingForm 6-K - Stock Titan
Aptorum, DiamiR publish glioblastoma blood test study By Investing.com - Investing.com South Africa
Aptorum, DiamiR publish glioblastoma blood test study - Investing.com Nigeria
Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania - Bitget
Blood test study takes aim at glioblastoma, deadliest brain cancer - Stock Titan
User - The Chronicle-Journal
Aptorum Group Receives Nasdaq Compliance Notification - Intellectia AI
APM | Aptorum Group Limited Class FinancialsIncome Statement - Quiver Quantitative
Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - The Chronicle-Journal
APM Should I Buy - Intellectia AI
Aptorum Group Limited (NASDAQ:APM) Short Interest Up 232.3% in February - Defense World
Aptorum Group Ltd (APM) Income Statement - TradingKey
APMAptorum Group Ltd Latest Stock News & Market Updates - Stock Titan
Can Aptorum Group Limited stock outperform in a bear marketTrade Risk Summary & Target Return Focused Stock Picks - mfd.ru
APM PE Ratio & Valuation, Is APM Overvalued - Intellectia AI
Exit Recap: Is Aptorum Group Limited forming a double bottom2025 Support & Resistance & Weekly Top Stock Performers List - baoquankhu1.vn
CEO Change: Will Aptorum Group Limited stock hit new highs in YEARTrade Performance Summary & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Aptorum Group schedules 2025 annual general meeting for March in Hong Kong By Investing.com - Investing.com South Africa
Aptorum Group schedules 2025 annual general meeting for March in Hong Kong - Investing.com
Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease - The Manila Times
Will Aptorum Group Limited outperform small cap indexes2025 Risk Factors & Precise Buy Zone Identification - mfd.ru
Andean Precious Metals Announces C$83.1 Million Bought Public Secondary Offering of Common Shares - markets.businessinsider.com
Trend Recap: Can Aptorum Group Limited continue delivering strong returnsJuly 2025 Intraday Action & Expert Approved Momentum Ideas - baoquankhu1.vn
Aptorum Group (NASDAQ:APM) vs. BioNxt Solutions (OTCMKTS:BNXTF) Head-To-Head Review - Defense World
Aptorum Group Ltd Stock (APM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):